Celldex Therapeutics (CLDX) Interest & Investment Income (2012 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Interest & Investment Income of -$1.1 million for Q1 2026, down 534.65% year-over-year from $254000.0 in Q1 2025, and up 95.09% quarter-over-quarter from -$22.5 million in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Interest & Investment Income (2012 - 2026) Analysis & Trends
Celldex Therapeutics' Interest & Investment Income history runs 15 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 534.65% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$17.2 million (down 144.69% YoY), while the FY2025 annual figure was $312000.0, down 99.16% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$1.1 million, up from -$22.5 million in the prior quarter.
- The five-year high for Interest & Investment Income was $35.2 million in Q4 2024, with the low at -$22.5 million in Q4 2025.
- The 5-year median for Interest & Investment Income is $63000.0 (2023), against an average of $1.5 million.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income plunged 89000.0% in 2022, then soared 5468.25% in 2024.
- Celldex Therapeutics' Interest & Investment Income stood at $1.4 million in 2022, then surged by 214.94% to $4.3 million in 2023, then jumped by 715.44% to $35.2 million in 2024, then sank by 163.75% to -$22.5 million in 2025, then soared by 95.09% to -$1.1 million in 2026.
- Business Quant data shows CLDX's Interest & Investment Income at -$1.1 million in Q1 2026, -$22.5 million in Q4 2025, and $6.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Celldex Therapeutics | 3.07 Bn | 3.07 Bn | -2.57 Mn | 7.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.12 Mn |
| Mar 31, 2026 | -1.10 Mn |
| Dec 31, 2025 | 5.84 Mn |
| Sep 30, 2025 | 6.57 Mn |
| Jun 30, 2025 | 7.26 Mn |
| Mar 31, 2025 | 254,000.00 |
| Dec 31, 2024 | 8.94 Mn |
| Sep 30, 2024 | 10.01 Mn |
| Jun 30, 2024 | -464,000.00 |
| Mar 31, 2024 | -1.06 Mn |
| Dec 31, 2023 | 4.32 Mn |
| Sep 30, 2023 | 2.98 Mn |
| Jun 30, 2023 | -51,000.00 |
| Mar 31, 2023 | 863,000.00 |
| Dec 31, 2022 | 4.92 Mn |
| Sep 30, 2022 | 912,000.00 |
| Jun 30, 2022 | -529,000.00 |
| Mar 31, 2022 | -1.78 Mn |
| Dec 31, 2021 | -1.01 Mn |
| Sep 30, 2021 | 145,000.00 |